Company Monitoring Page for Bluebird-Bio

latest headlines for company on cafepharma

Court ruling on bluebird bio’s gene therapy marketing campaign 'sparks' dismay at Roche's Spark
Fierce Pharma
Thu, 01/27/22 - 10:38 am
Tags:
Bluebird Bio, gene therapy, sickle cell disease, Roche, Spark Therapeutics
No stranger to headwinds, bluebird runs into two PDUFA delays unrelated to new safety issues
Endpoints
Tue, 01/18/22 - 10:40 am
Tags:
Bluebird Bio, beti-cel, eli-cel, FDA, gene therapy, beta thalassemia
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches
Fierce Pharma
Thu, 01/13/22 - 10:32 pm
Tags:
JPMHC 2022, Bluebird Bio, gene therapy, sickle cell disease, beti-cel
JPM22, Day 2: Sanofi's dealmaking priorities, bluebird's gene therapy goals and more
Fierce Pharma
Tue, 01/11/22 - 11:37 am
Tags:
JPMHC 2022, GSK, Sanofi, Bluebird Bio
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first
Fierce Pharma
Tue, 01/11/22 - 11:31 am
Tags:
Bluebird Bio, JPMHC 2022, Pharma CEOs, Europe, Zynteglo
4 Biotechs That Were Winners at ASH
Motley Fool
Mon, 01/3/22 - 10:38 am
Tags:
ASH2021, Bristol Myers Squibb, Agios Pharmaceuticals, Forma Therapeutics, Bluebird Bio, sickle cell disease, Multiple Myeloma
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
Yahoo Finance
Mon, 12/20/21 - 10:54 am
Tags:
Bluebird Bio, lovo-cel, gene therapy, sickle cell disease, FDA, clinical hold, clinical trials
ASH 2021 – Bluebird looks to revive Lentiglobin
EP Vantage
Mon, 12/13/21 - 10:34 am
Tags:
Bluebird Bio, LentiGlobin, ASH2021, sickle cell disease
Bluebird bio may finally get a gene therapy approved in the US
Endpoints
Mon, 11/22/21 - 10:28 am
Tags:
Bluebird Bio, gene therapy, FDA, Zynteglo, beta-thalassemia, priority review
With oncology spinoff done, bluebird bio moves to new digs better suited to its future
Fierce Pharma
Sun, 11/7/21 - 10:50 pm
Tags:
Bluebird Bio, oncology, Cambridge
Bluebird bio completes spinout of oncology business 2seventy bio
Bizjournals
Fri, 11/5/21 - 12:00 am
Tags:
Bluebird Bio, spinoff, oncology, 2seventy bio
Bluebird, winding down in Europe, withdraws another rare disease gene therapy
BioPharma Dive
Thu, 10/21/21 - 11:17 pm
Tags:
Bluebird Bio, gene therapy, Europe, Skysona, cerebral adrenoleukodystrophy
bluebird bio provides update on 2seventy bio spin-off
PM Live
Tue, 10/12/21 - 11:49 pm
Tags:
Bluebird Bio, 2seventy bio, spinoff, oncology
Bluebird bio Takes Hit with FDA Clinical Hold on Gene Therapy
BioSpace
Mon, 08/9/21 - 11:48 pm
Tags:
Bluebird Bio, FDA, clinical hold, gene therapy, eli-cel, cerebral adrenoleukodystrophy
Resilience shells out $110M for bluebird bio site, kickstarting new collaboration
Endpoints
Thu, 07/29/21 - 11:05 am
Tags:
resilience, Bluebird Bio, drug manufacturing, lentiviral, North Carolina
Bluebird, with little fanfare, is first to bring a second gene therapy to market
BioPharma Dive
Wed, 07/21/21 - 08:43 pm
Tags:
Europe, Bluebird Bio, Skysona, cerebral adrenoleukodystrophy, gene therapy
With LentiGlobin cleared by FDA, bluebird lifts EU marketing hold on gene therapy using the same delivery mechanism
Endpoints
Fri, 07/9/21 - 09:54 am
Tags:
Bluebird Bio, LentiGlobin, sickle cell disease, Zynteglo, Europe, beta thalassemia
bluebird bio Responds to Marketing Campaign Lawsuit with Countersuit
BioSpace
Wed, 07/7/21 - 10:25 pm
Tags:
pharma marketing, Bluebird Bio, Spark Therapeutics, Roche
Bluebird's Zynteglo trials set to resume, putting gene therapy back on flight path to FDA filing
Fierce Pharma
Mon, 06/7/21 - 11:09 am
Tags:
Bluebird Bio, Zynteglo, gene therapy, beta-thalassemia
Bluebird’s new gene therapy among three new EMA OKs ahead of FDA
Endpoints
Fri, 05/21/21 - 10:56 am
Tags:
gene therapy, Bluebird Bio, EMA, GSK, Vir, COVID-19, Skysona, monoclonal antibodies, Bylvay

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.